Document registry — page 20
Every document the Institute has published, 1,631 in total, with its identifier, type, certainty rating and review date.
Documents
-
Record of documents ratified in the 2025 Q4 assessment cycle.
22 Dec 2025 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary…
Very low21 Dec 2025 -
Purity determination for peptides not retained by conventional reverse-phase chromatography
High20 Dec 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in knee osteoarthritis and obesity over 68 weeks. Primary result: Improvement relative to…
Low19 Dec 2025 -
Consultation on the draft of this analytical evidence review, which registers the question: What proportion of certificates of analysis supplied with research peptides…
12 Dec 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in peripheral arterial disease and type 2 diabetes over as stated in the parent protocol. The…
Very low09 Dec 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in peripheral arterial disease and type 2 diabetes randomising 792 participants over 52 weeks…
Moderate08 Dec 2025 -
Genetically determined impairment of oxidative phosphorylation producing myopathy, exercise intolerance or multisystem disease.
07 Dec 2025 -
Small-molecule nicotinamide N-methyltransferase inhibitor. NNMT methylates nicotinamide, diverting it from NAD+ salvage and generating 1-methylnicotinamide. Inhibiting NNMT is proposed to raise cellular NAD+…
Very low07 Dec 2025 -
Phase 1 ascending dose, phase 1 study of Semaglutide, oral in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low03 Dec 2025 -
In the population defined for cutaneous wound healing and tissue repair, what is the incidence of adverse events leading to discontinuation with GHK-Cu compared with its…
Low02 Dec 2025 -
Event-driven cardiovascular outcome trial, phase 3 study of Tirzepatide in cardiovascular and type 2 diabetes randomising 13,299 participants over median 4.5 years…
Moderate28 Nov 2025 -
Consultation on the draft standard for bacterial endotoxin testing of peptide presentations, which specifies the performance a determination must achieve and the…
23 Nov 2025 -
Consultation on the draft monograph for Ipamorelin, which the assessment committee released for public comment before ratification. The draft grades the compound's…
23 Nov 2025 -
In the population defined for inflammatory bowel disease and mucosal barrier disorders, is the effect of Teduglutide maintained across the full duration of the…
Moderate22 Nov 2025 -
In the population defined for type 2 diabetes mellitus, what is the effect of CagriSema (cagrilintide with semaglutide) compared with the comparator used in its…
Moderate20 Nov 2025 -
In the population defined for hiv-associated lipodystrophy and excess visceral adiposity, what is the effect of Tesamorelin compared with the comparator used in its…
Moderate19 Nov 2025 -
Dual glucagon and GLP-1 receptor agonist (acylated). Glucagon receptor agonism increases hepatic fatty-acid oxidation, resting energy expenditure and hepatic lipid clearance; GLP-1 receptor agonism…
Moderate19 Nov 2025 -
Single-arm open-label, phase 3 study of Mazdutide in obesity over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low18 Nov 2025 -
In the population defined for obesity and overweight in adults, is the effect of Retatrutide maintained across the full duration of the contributing trials?
Moderate16 Nov 2025 -
In the population defined for obesity and overweight in adults, is the effect of Liraglutide maintained across the full duration of the contributing trials?
High15 Nov 2025 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the effect of Tirzepatide compared with the comparator…
Moderate13 Nov 2025 -
In the population defined for primary mitochondrial myopathy and bioenergetic disorders, what is the effect of SS-31 (elamipretide) compared with the comparator used in…
Moderate11 Nov 2025 -
Peptides, SARMs, injectable oils and raw materials.
11 Nov 2025 -
Consultation on the draft synthesis of weight trajectory after an incretin receptor agonist is stopped. The contributing evidence is drawn principally from the…
05 Nov 2025 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the effect of Semaglutide, oral compared with the…
Moderate01 Nov 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Ecnoglutide in obesity randomising 664 participants over 48 weeks. Primary result: Mean change −13.2 % at…
Low01 Nov 2025 -
Adiposity above the 95th percentile for age and sex, or above the 120th percentile of the 95th percentile for severe obesity, in individuals under 18 years.
31 Oct 2025 -
Consultation on the draft monograph for Thymalin, which the assessment committee released for public comment before ratification. The draft grades the compound's…
25 Oct 2025 -
In adults at elevated cardiovascular risk, what is the effect of a glucagon-like peptide-1 receptor agonist compared with placebo on major adverse cardiovascular events?
High24 Oct 2025 -
Consultation on the draft monograph for CagriSema (cagrilintide with semaglutide), which the assessment committee released for public comment before ratification. The…
22 Oct 2025 -
In the population defined for obesity and overweight in adults, what is the effect of Semaglutide compared with the comparator used in its contributing trials on the…
High22 Oct 2025 -
In the population defined for obesity and overweight in adults, what is the effect of CagriSema (cagrilintide with semaglutide) compared with the comparator used in its…
Moderate17 Oct 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of CagriSema (cagrilintide with semaglutide) in obesity and type 2 diabetes over as stated in the parent…
Very low15 Oct 2025 -
Consultation on the draft monograph for Semax, which the assessment committee released for public comment before ratification. The draft grades the compound's principal…
14 Oct 2025 -
Acetylated heptapeptide fragment of thymosin beta-4. Thymosin beta-4 is an abundant intracellular actin-sequestering protein with reported extracellular activity in angiogenesis, cell migration and…
Very low13 Oct 2025 -
What is the incidence of gastrointestinal adverse events and of discontinuation for adverse events with incretin receptor agonists compared with placebo?
High12 Oct 2025 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the effect of Kisspeptin-10 compared with the comparator…
11 Oct 2025 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Tirzepatide compared with its comparator?
High09 Oct 2025 -
Observational, phase 3 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low07 Oct 2025
page 20 of 41